ALS Mechanistic Pathway

Migration, Crosslink

📖

ALS Mechanistic Pathway

active

wiki page Created: 2026-04-02T07:19:53 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-als-pathway

📖 Wiki Page

mechanism1086 wordssynced 2026-04-02

ALS Mechanistic Pathway

Introduction

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive loss of upper and lower motor neurons. This pathway models the molecular mechanisms underlying motor neuron degeneration in ALS[@cleveland2001].

Overview

ALS mechanisms involve multiple interconnected processes: [@boillee2006]

Protein Aggregation: TDP-43, SOD1, FUS, C9orf72 DPR proteins form cytoplasmic inclusions
RNA Metabolism Dysregulation: Defects in RNA processing, splicing, and transport
Mitochondrial Dysfunction: Energy deficits, oxidative stress, mitophagy impairment
Excitotoxicity: Glutamate-induced calcium dysregulation, EAAT2 loss
Neuroinflammation: Activated microglia and astrocytes releasing pro-inflammatory cytokines
Axonal Transport Defects: Impaired transport of proteins, organelles
Neuronal Death: Progressive loss of cortical and spinal motor neurons

Pathway Diagram

Mechanism

flowchart TD A["Genetic Mutations"] --> B["SOD1 Misfolding"] A --> C["TDP-43 Mislocalization"] A --> D["C9orf72 Repeat Expansion"] A --> E["FUS Aggregation"] C --> F["RNA Processing Defects"] D --> G["Dipeptide Repeat Toxicity"] B --> H["Protein Aggregation"] E --> F F --> H G --> H H --> I["Motor Neuron Stress"] J["EAAT2 Loss"] --> K["Glutamate Excitotoxicity"] K --> I I --> L["Mitochondrial Dysfunction"] I --> M["Axonal Transport Failure"] L --> N["Motor Neuron Death"] M --> N

...

ALS Mechanistic Pathway

Introduction

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive loss of upper and lower motor neurons. This pathway models the molecular mechanisms underlying motor neuron degeneration in ALS[@cleveland2001].

Overview

ALS mechanisms involve multiple interconnected processes: [@boillee2006]

Protein Aggregation: TDP-43, SOD1, FUS, C9orf72 DPR proteins form cytoplasmic inclusions
RNA Metabolism Dysregulation: Defects in RNA processing, splicing, and transport
Mitochondrial Dysfunction: Energy deficits, oxidative stress, mitophagy impairment
Excitotoxicity: Glutamate-induced calcium dysregulation, EAAT2 loss
Neuroinflammation: Activated microglia and astrocytes releasing pro-inflammatory cytokines
Axonal Transport Defects: Impaired transport of proteins, organelles
Neuronal Death: Progressive loss of cortical and spinal motor neurons

Pathway Diagram

Mechanism

Mermaid diagram (expand to render)

Key Molecular Players

| Protein/Gene | Role in ALS | Therapeutic Target | [@ilieva2009]
|--------------|-------------|-------------------| [@ling2013]
| TDP-43 | RNA-binding protein; forms cytoplasmic inclusions in 95% of ALS | ASO, aggregation inhibitors | [@taylor2016]
| SOD1 | Superoxide dismutase; mutant causes familial ALS | Gene silencing, copper chelators | [@van2017]
| FUS | RNA-binding protein; mutations cause FUS-ALS | ASO, modulators | [@mejzini2019]
| C9orf72 | Hexanucleotide repeat causes ALS/FTD | ASO, gene therapy | [@ghasemi2018]
| EAAT2 | Glutamate transporter; loss causes excitotoxicity | Ceftriaxone, gene therapy | [@liu2022]
| OPTN | Autophagy receptor; mutations cause ALS | Autophagy modulators |
| UBQLN2 | Autophagy receptor; mutations cause ALS | Proteostasis enhancers |

Disease Mechanisms

Protein Aggregation

TDP-43 Pathology (95% of ALS cases)

TDP-43 mislocalizes from nucleus to cytoplasm
Forms phosphorylated, ubiquitinated inclusions
Sequesters RNA and RNA-binding proteins
Causes loss of nuclear TDP-43 function

SOD1 Mutations (20% of familial ALS)

Gain-of-toxic-function through misfolding
Forms insoluble aggregates
Impaired axonal transport
Mitochondrial dysfunction

FUS Pathology

FUS inclusions in cytoplasm
Impaired RNA splicing
Defects in RNA transport

C9orf72 DPR Toxicity

Hexanucleotide repeat expansion
RNA foci sequester RNA-binding proteins
Dipeptide repeat (DPR) proteins are toxic
Nucleolar stress

RNA Metabolism Dysregulation

Splicing Defects: Aberrant mRNA splicing due to TDP-43/FUS loss
Transport Defects: Impaired RNA granule transport
Translation Dysregulation: Altered protein synthesis
Non-coding RNA Dysfunction: miRNA processing defects

Mitochondrial Dysfunction

Energy Depletion: Reduced ATP production
Oxidative Stress: Increased ROS from Complex I
Calcium Buffering: Impaired calcium handling
Mitophagy Defects: Impaired clearance of damaged mitochondria
Axonal Mitochondria: Specific vulnerability

Excitotoxicity

EAAT2 Loss: Reduced glutamate uptake by astrocytes
AMPA Receptor Dysfunction: Enhanced calcium permeability
NMDA Receptor Overactivation: Excessive calcium influx
Metabotropic Receptor Dysregulation: Group I mGluR effects

Neuroinflammation

Microglial Activation: Pro-inflammatory phenotype (M1)
Astrocytic Reactivity: Loss of supportive functions
Cytokine Release: IL-1β, TNF-α, IL-6, CCL2
Complement Activation: C1q-mediated synapse loss
TREM2 Dysfunction: Impaired microglial phagocytosis

Axonal Transport Defects

Kinesin/Dynein Dysfunction: Impaired anterograde/retrograde transport
Organelle Accumulation: Swollen axons, spheroids
Synaptic Vesicle Depletion: Impaired neurotransmitter release
Mitochondrial Transport Failure: Energy deficit in distal axons

Therapeutic Strategies

| Approach | Examples | Status |
|----------|----------|--------|
| Gene Silencing | Tofersen (SOD1 ASO), BIIB056 (SOD1), ASO for C9orf72 | FDA approved (tofersen), Clinical trials |
| Aggregation Inhibitors | Small molecules, peptides | Preclinical |
| Excitotoxicity Blockers | Riluzole, Edaravone | FDA approved |
| Neurotrophic Factors | AAV-GDNF, AAV-BDNF | Preclinical |
| Microglial Modulation | TREM2 agonists, CD33 antagonists | Discovery |
| Mitochondrial Protectants | CoQ10, MitoQ, Edaravone | Clinical trials |
| Autophagy Enhancement | Rapamycin, TFEB activators | Preclinical |
| Astrocyte Reprogramming | Astrocyte-to-neuron conversion | Discovery |

Cross-References

[TDP-43](/proteins/tdp-43-protein) - TDP-43 protein page
[SOD1](/genes/sod1) - SOD1 gene page
[FUS](/genes/fus) - FUS gene page
[C9orf72](/genes/c9orf72) - C9orf72 gene page
[Excitotoxicity Pathway](/mechanisms/excitotoxicity-pathway) - Related mechanism
[Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway) - Related mechanism
[RNA Metabolism Dysregulation](/mechanisms/rna-metabolism-dysregulation) - Related mechanism
[Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction) - Related mechanism
[ALS Disease](/diseases/amyotrophic-lateral-sclerosis) - Main disease page

Key Publications

[Rowland LP, Shneider NA. Amyotrophic lateral sclerosis (2001)](https://pubmed.ncbi.nlm.nih.gov/11274045/) — N Engl J Med[@rowland2001]

[Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron vulnerability in ALS (2001)](https://pubmed.ncbi.nlm.nih.gov/11737005/) — Nat Rev Neurosci[@cleveland2001]

[Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors (2006)](https://pubmed.ncbi.nlm.nih.gov/16815314/) — Neuron[@boillee2006]

[Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond (2009)](https://pubmed.ncbi.nlm.nih.gov/19635952/) — J Cell Biol[@ilieva2009]

[Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis (2013)](https://pubmed.ncbi.nlm.nih.gov/24288922/) — Neuron[@ling2013]

[Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism (2016)](https://pubmed.ncbi.nlm.nih.gov/28029927/) — Nature[@taylor2016]

[Van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis (2017)](https://pubmed.ncbi.nlm.nih.gov/28542893/) — Lancet[@van2017]

[Mejzini R, Flynn LL, Pitout IL, et al. ALS genetics, mechanisms, and therapeutics: where are we now? (2019)](https://pubmed.ncbi.nlm.nih.gov/31849657/) — Front Neurosci[@mejzini2019]

[Ghasemi M, Brown RH Jr. Genetics of amyotrophic lateral sclerosis (2018)](https://pubmed.ncbi.nlm.nih.gov/29507226/) — Cold Spring Harb Perspect Med[@ghasemi2018]

[Liu J, et al. Therapeutic strategies for amyotrophic lateral sclerosis: from small molecules to disease-modifying therapies (2022)](https://pubmed.ncbi.nlm.nih.gov/35231969/) — Nat Rev Drug Discov[@liu2022]

Replication and Evidence

Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.

However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.

Recent Research Updates (2024-2026)

Recent publications:

[Elevated serum trimethylamine N-oxide (TMAO) and trimethyllysine in patients with ALS. (2026)](https://pubmed.ncbi.nlm.nih.gov/41705073/) — IBRO neuroscience reports PMID: 41705073(https://pubmed.ncbi.nlm.nih.gov/41705073/)

[Neuromodulatory role and therapeutic potential of N6-methyladenosine RNA methylation in neurodegenerative diseases. (2026)](https://pubmed.ncbi.nlm.nih.gov/40618260/) — Neural regeneration research PMID: 40618260(https://pubmed.ncbi.nlm.nih.gov/40618260/)

[The role of gut microbiota-mitochondria crosstalk in neurodegeneration. (2026)](https://pubmed.ncbi.nlm.nih.gov/40314217/) — Neural regeneration research PMID: 40314217(https://pubmed.ncbi.nlm.nih.gov/40314217/)

[Neuroinflammation in neurodegenerative diseases: Focusing on the mediation of T lymphocytes. (2026)](https://pubmed.ncbi.nlm.nih.gov/40536931/) — Neural regeneration research PMID: 40536931(https://pubmed.ncbi.nlm.nih.gov/40536931/)

slug	mechanisms-als-pathway
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b52b8f791143
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-als-pathway'}
_schema_version	1

📗 Cite This Artifact

ALS Mechanistic Pathway

ALS Mechanistic Pathway

Introduction

Overview

Pathway Diagram

Mechanism

ALS Mechanistic Pathway

Introduction

Overview

Pathway Diagram

Mechanism

Key Molecular Players

Disease Mechanisms

Protein Aggregation

RNA Metabolism Dysregulation

Mitochondrial Dysfunction

Excitotoxicity

Neuroinflammation

Axonal Transport Defects

Therapeutic Strategies

Cross-References

Key Publications

Replication and Evidence

Recent Research Updates (2024-2026)

See Also

💬 Discussion